244 related articles for article (PubMed ID: 23687519)
1. Drug-like property profiling of novel neuroprotective compounds to treat acute ischemic stroke: guidelines to develop pleiotropic molecules.
Lapchak PA
Transl Stroke Res; 2013 Jun; 4(3):328-42. PubMed ID: 23687519
[TBL] [Abstract][Full Text] [Related]
2. A series of novel neuroprotective blood brain barrier penetrating flavonoid drugs to treat acute ischemic stroke.
Lapchak PA
Curr Pharm Des; 2012; 18(25):3694-703. PubMed ID: 22574983
[TBL] [Abstract][Full Text] [Related]
3. A novel approach to screening for new neuroprotective compounds for the treatment of stroke.
Maher P; Salgado KF; Zivin JA; Lapchak PA
Brain Res; 2007 Oct; 1173():117-25. PubMed ID: 17765210
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome P450-mediated herb-drug interaction (HDI) of Polygonum multiflorum Thunb. based on pharmacokinetic studies and in vitro inhibition assays.
Xing Y; Yu Q; Zhou L; Cai W; Zhang Y; Bi Y; Zhang Y; Fu Z; Han L
Phytomedicine; 2023 Apr; 112():154710. PubMed ID: 36805481
[TBL] [Abstract][Full Text] [Related]
5. Clinical trials in acute ischemic stroke.
Kikuchi K; Tanaka E; Murai Y; Tancharoen S
CNS Drugs; 2014 Oct; 28(10):929-38. PubMed ID: 25160686
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotective and neurotrophic curcuminoids to treat stroke: a translational perspective.
Lapchak PA
Expert Opin Investig Drugs; 2011 Jan; 20(1):13-22. PubMed ID: 21158690
[TBL] [Abstract][Full Text] [Related]
7. De-Risking of Stilbazulenyl Nitrone (STAZN), a Lipophilic Nitrone to Treat Stroke Using a Unique Panel of In Vitro Assays.
Lapchak PA; Schubert DR; Maher PA
Transl Stroke Res; 2011 Jun; 2(2):209-17. PubMed ID: 22003372
[TBL] [Abstract][Full Text] [Related]
8. Potential for brain accessibility and analysis of stability of selected flavonoids in relation to neuroprotection in vitro.
Pogačnik L; Pirc K; Palmela I; Skrt M; Kim KS; Brites D; Brito MA; Ulrih NP; Silva RF
Brain Res; 2016 Nov; 1651():17-26. PubMed ID: 27639810
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotection in cerebral ischaemia: facts and fancies--the need for new approaches.
Wahlgren NG; Ahmed N
Cerebrovasc Dis; 2004; 17 Suppl 1():153-66. PubMed ID: 14694293
[TBL] [Abstract][Full Text] [Related]
10. The Natural Flavonoid Pinocembrin: Molecular Targets and Potential Therapeutic Applications.
Lan X; Wang W; Li Q; Wang J
Mol Neurobiol; 2016 Apr; 53(3):1794-1801. PubMed ID: 25744566
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotective Strategies for Stroke by Natural Products: Advances and Perspectives.
Liu A; Hu J; Yeh TS; Wang C; Tang J; Huang X; Chen B; Huangfu L; Yu W; Zhang L
Curr Neuropharmacol; 2023; 21(11):2283-2309. PubMed ID: 37458258
[TBL] [Abstract][Full Text] [Related]
12. Α-aryl-N-alkyl nitrones, as potential agents for stroke treatment: synthesis, theoretical calculations, antioxidant, anti-inflammatory, neuroprotective, and brain-blood barrier permeability properties.
Chioua M; Sucunza D; Soriano E; Hadjipavlou-Litina D; Alcázar A; Ayuso I; Oset-Gasque MJ; González MP; Monjas L; Rodríguez-Franco MI; Marco-Contelles J; Samadi A
J Med Chem; 2012 Jan; 55(1):153-68. PubMed ID: 22126405
[TBL] [Abstract][Full Text] [Related]
13. Bush mint (Hyptis suaveolens) and spreading hogweed (Boerhavia diffusa) medicinal plant extracts differentially affect activities of CYP1A2, CYP2D6 and CYP3A4 enzymes.
Ekow Thomford N; Dzobo K; Adu F; Chirikure S; Wonkam A; Dandara C
J Ethnopharmacol; 2018 Jan; 211():58-69. PubMed ID: 28942133
[TBL] [Abstract][Full Text] [Related]
14. HepG2 cells simultaneously expressing five P450 enzymes for the screening of hepatotoxicity: identification of bioactivable drugs and the potential mechanism of toxicity involved.
Tolosa L; Gómez-Lechón MJ; Pérez-Cataldo G; Castell JV; Donato MT
Arch Toxicol; 2013 Jun; 87(6):1115-27. PubMed ID: 23397584
[TBL] [Abstract][Full Text] [Related]
15. Potential Biological Targets Prediction,
Yousuf M; Rafi S; Ishrat U; Shafiga A; Dashdamirova G; Leyla V; Iqbal H
Med Chem; 2022; 18(2):288-305. PubMed ID: 34102986
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotective effects of AT1 receptor antagonists after experimental ischemic stroke: what is important?
Culman J; Jacob T; Schuster SO; Brolund-Spaether K; Brolund L; Cascorbi I; Zhao Y; Gohlke P
Naunyn Schmiedebergs Arch Pharmacol; 2017 Sep; 390(9):949-959. PubMed ID: 28669009
[TBL] [Abstract][Full Text] [Related]
17. Biopharmaceutical characterization of decursin and their derivatives for drug discovery.
Mahat B; Chae JW; Baek IH; Song GY; Song JS; Ma JY; Kwon KI
Drug Dev Ind Pharm; 2013 Oct; 39(10):1523-30. PubMed ID: 23003006
[TBL] [Abstract][Full Text] [Related]
18. Blood-Brain Barrier Transporters: Opportunities for Therapeutic Development in Ischemic Stroke.
Nilles KL; Williams EI; Betterton RD; Davis TP; Ronaldson PT
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163820
[TBL] [Abstract][Full Text] [Related]
19. J-147 a Novel Hydrazide Lead Compound to Treat Neurodegeneration: CeeTox
Lapchak PA; Bombien R; Rajput PS
J Neurol Neurophysiol; 2013 Aug; 4(3):. PubMed ID: 25364619
[TBL] [Abstract][Full Text] [Related]
20. Emerging agents for the treatment and prevention of stroke: progress in clinical trials.
Safouris A; Magoufis G; Tsivgoulis G
Expert Opin Investig Drugs; 2021 Oct; 30(10):1025-1035. PubMed ID: 34555978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
